Merck KGaA (OTCMKTS:MKGAF) Sees Large Growth in Short Interest

Merck KGaA (OTCMKTS:MKGAF) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 253,200 shares, an increase of 26.9% from the August 31st total of 199,600 shares. Based on an average trading volume of 300 shares, the short-interest ratio is currently 844.0 days.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group upgraded shares of Merck KGaA to a “strong-buy” rating in a research report on Thursday, September 19th.

Merck KGaA Trading Down 1.2 %

Merck KGaA stock traded down $2.07 during trading hours on Monday, reaching $176.13. 100 shares of the company’s stock were exchanged, compared to its average volume of 572. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $22.76 billion, a PE ratio of 25.86 and a beta of 0.96. Merck KGaA has a twelve month low of $143.46 and a twelve month high of $200.56. The firm’s 50 day simple moving average is $184.75 and its 200 day simple moving average is $175.55.

Merck KGaA (OTCMKTS:MKGAF) last announced its quarterly earnings results on Thursday, August 1st. The company reported $1.51 EPS for the quarter. The firm had revenue of $5.76 billion during the quarter. Merck KGaA had a net margin of 12.60% and a return on equity of 10.17%. Research analysts predict that Merck KGaA will post 9.5 earnings per share for the current year.

Merck KGaA Company Profile

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.